Trials / Completed
CompletedNCT00359190
Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer
A Phase I, Open Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of GW572016 in Once Daily Versus Twice Daily Dosing Regimens in Patients With Treatment- Naive Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the inhibition of ErbB1 and ErbB2 phosphorylation and downstream mediators of tumor cell growth and survival tumor tissue in treatment-naive breast cancer patients for three dosing schedules of lapatinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lapatinib | GW572016 ditosylate salt (lapatinib) will be given as 250 mg tablets via oral route |
Timeline
- Start date
- 2004-06-29
- Primary completion
- 2008-01-09
- Completion
- 2008-01-09
- First posted
- 2006-08-01
- Last updated
- 2017-11-13
Locations
10 sites across 2 countries: United States, Israel
Source: ClinicalTrials.gov record NCT00359190. Inclusion in this directory is not an endorsement.